Medical oncologist - Views my own.
Joined February 2022
- Tweets413
- Following314
- Followers236
- Likes2.9K
Emeline COLOMBA retweeted
(Breast) Cancer care shouldn’t be a luxury.
We lose lives not just to cancer, but to lack of access, high costs, and trials that exclude too many.
Innovation must reach every patient, everywhere!
@Nature @curijoey @LoiSher @myESMO @ASCO @BreastCancerNow @tmprowell @uicc
nature.com/articles/s41523-0…
Emeline COLOMBA retweeted
The mechanisms by which ultra-processed foods (UPF) drive obesity, an outstanding review article
"the evidence is sufficiently strong to justify immediate public health efforts to reduce UPF consumption."
nature.com/articles/s41574-0…
Emeline COLOMBA retweeted
🦠 The gut isn’t just digestion, it’s defense.
Microbiome = hidden player in cancer care.
➡️ Shapes immunity, response, toxicity, survival.
🧪 Fiber, FMT, even bacteria-based drugs are in the game now.
#Cancer #Immunotherapy #Microbiome #Oncology #GutHealth @JAMA_current @OncoAlert
doi:10.1001/jama.2025.2191
Emeline COLOMBA retweeted
🧵@Institut_cancer se félicite de l’adoption par l’@AssembleeNat de la proposition de loi portant création du registre national des cancers. Il en assurera le pilotage et la mise en œuvre. Cela représente un bond dans la surveillance épidémiologique des cancers sur le territoire.
Emeline COLOMBA retweeted
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
ascopubs.org/doi/10.1200/JCO…
This phase I trial of pasritamig, a novel bispecific T-cell–engaging antibody targeting KLK2 in metastatic castration-resistant #prostateCancer , demonstrated a manageable safety profile with mostly low-grade adverse events and minimal cytokine release syndrome.
Showed promising preliminary antitumor activity, including a 42.4% PSA response rate and a median radiographic progression-free survival of 7.85 months, supporting further clinical development.
@drmnstein
@DebbieRobbrecht
@DogerStart
@MikeSchweizerMD
@EmilianoCalvo_
@meavdongen
@DrDariaGaut
Ping @OncoAlert 🚨
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima
Emeline COLOMBA retweeted
💬 Le parcours FRESH illustre pleinement notre engagement à étendre la médecine de précision pour tous les patients atteints de #cancer en France et à l’international, quels que soient leur lieu de vie et leur situation clinique.
⬇
📰 Moins d’un an après son lancement, le parcours FRESH étend l’accès à la médecine de précision sur tout le territoire, métropolitain et ultramarin.
Lire le communiqué de presse ➡ gustaveroussy.fr/fr/moins-du…
Emeline COLOMBA retweeted
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
Emeline COLOMBA retweeted
#ASCO25
Many new drugs ➡️ welcome but marginal gains. 💰 Cost + ☣️ toxicity
Exercise ➡️ marginal cost + negligible toxicity
✅ Evidence based intervention should be added to standard treatment recommendations
No need to wait for regulatory approval! Do it now!
Presented at #ASCO25:
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL
@ASCO
Emeline COLOMBA retweeted
Organ preservation dream becoming reality!
Neoadjuvant PD-1 blockade led to nonoperative management in 80% of early-stage dMMR solid tumors.
92% recurrence-free survival at 2 years.
Surgery was not needed: dignity, function, and hope preserved.
@NEJM @gonen_mithat @MSKCancerCenter @OncoAlert @AACR #AACR25
nejm.org/doi/full/10.1056/NE…
Emeline COLOMBA retweeted
📰 « J’étais à mille lieues d’imaginer que j’avais un #cancer » : le difficile diagnostic de la maladie chez les adultes jeunes.
Retrouvez l'expertise de la Dr Cristina Smolenschi, via le projet Yoda, dans un article de @libe ⤵ liberation.fr/societe/sante/…
Emeline COLOMBA retweeted
Lifestyle is a stronger predictor of aging and mortality than genetics.
A new Nature study of ~500,000 people found:
🎯 17% of mortality variation was linked to lifestyle (exposome).
🧬 <2% of was explained by genetics.
Here’s what you need to know 👇🧵 1/10
Emeline COLOMBA retweeted
🗓️ #Comité #Scientifique du GINECO
🔎 En 2024, nous avons mené des essais cliniques majeurs pour améliorer la prise en charge des cancers gynécologiques et métastatiques du sein. De nouvelles perspectives se dessinent pour 2025 avec des avancées thérapeutiques prometteuses en recherche clinique et translationnelle.
👏 Félicitations au Pr Isabelle Ray-Coquard et au Dr Anne-Claire Hardy-Bessard pour leur #leadership et leur #dévouement à porter toujours plus haut le groupe GINECO au cours des six dernières années. Et bienvenue au Pr Alexandra Leary et au Dr Laurence Gladieff dans leurs nouvelles fonctions de présidente et vice-présidente !
Emeline COLOMBA retweeted
Early-onset colorectal cancer (<50 yrs) is rising, linked to factors like Western diets, obesity, and gut microbiota changes. Prevention & early detection strategies are vital. #ColorectalCancer #Oncology #CancerPrevention @OncoAlert @NatRevClinOncol @ColonCancerFdn
rdcu.be/d49OZ
Emeline COLOMBA retweeted
No Better way to start 2025
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer
A Report from #APCCC24 LINK TO ARTICLE👇👇👇
sciencedirect.com/science/ar…
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore Eric Small Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul Consuelo Buttigliero Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis Susan Halabi Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal Fernando C. Maluf ,
@quimmateo
David Matheson, Mika P. Matikainen , Ray McDermott,
@DrRanaMcKay
Niven Mehra,
@amerseburger
@CaPsurvivorship
Michael J. Morris , Hind Mrabti, Deborah Mukherji
@declangmurphy
Vedang Murthy Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemur
@DrYukselUrun
Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero
@AOmlin
Emeline COLOMBA retweeted
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇👇👇👇👇👇👇
sciencedirect.com/science/ar…
NOW ON FINAL SESSION of #PROSCA24
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking.
The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting.
The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer.
Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore
Eric Small
Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis
Ana Aparicio
Andrew J. Armstrong
Diogo Assed Bastos
Gerhardt Attard
Karol Axcrona
Mouna Ayadi
Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul
Consuelo Buttigliero
Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng
Kim N. Chi
Caroline S. Clarke
Noel Clarke
Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke
Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun
Felix Y. Feng
Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis
Susan Halabi
Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope
Lisa G. Horvath
Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones
Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal
Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78,
Mika P. Matikainen 79,
Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship
Michael J. Morris 85,
Hind Mrabti 86,
Deborah Mukherji
@declangmurphy
Vedang Murthy
Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan
Anwar R. Padhani
Chris Parker
Darren M.C. Poon
Colin C. Pritchard
Danny M Rabah
Dana Rathkopf
Robert E. Reiter
Raphaele Renard-Penna
Charles J. Ryan
Fred Saad
Juan Pablo Sade
Shahneen Sandhu
Oliver A. Sartor
Edward Schaeffer
Howard I. Scher
Nima Sharifi
Iwona A. Skoneczna
Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki
Mary-Ellen Taplin
Camilla Thellenberg-Karlsson
Derya Tilki
Levent N. Türkeri
Hiroji Uemura
@DrYukselUrun
Claire L. Vale
Neha Vapiwala
Jochen Walz
Kosj Yamoah
Dingwei Ye
Evan Y. Yu
Almudena Zapatero
@AOmlin
Emeline COLOMBA retweeted
🧬Feeding the Gut to Fuel the Brain 🧠 An in-depth review in @NatMetabolism uncovers how the diet-microbiota-gut-brain axis influences brain health, linking dietary habits with cognitive and emotional well-being through gut-brain communication. 🌱
📖 Highlights
• Poor diets may worsen neuropsychiatric disorders, while specific nutrients can enhance cognition and mood.
• Mechanisms: How gut microbiota composition, modifiable by diet, impacts signaling to the brain, potentially preventing or managing cognitive decline.
• Clinical Potential: Personalized dietary interventions may be a promising frontier for brain health therapies.
✨ An essential read for those in integrative medicine, neuroscience, and nutrition science—especially given the rapid evolution of gut-brain axis research!
🔗 Check out the full review: zurl.co/Uge1
@E_MSchneider @kjdoriordan @jfcryan @Pharmabiotic
Emeline COLOMBA retweeted
We are very proud that the paper is online! Sincere thanks to our scientific committee and all panellists. Manuscript is open access, please use and distribute it! Hope to see you at the first edition of @APCCC_Lugano Diagnostics @ProfKHerrmann @stefanofanti4
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇👇👇👇👇👇👇
sciencedirect.com/science/ar…
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking.
The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting.
The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer.
Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore
Eric Small
Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis
Ana Aparicio
Andrew J. Armstrong
Diogo Assed Bastos
Gerhardt Attard
Karol Axcrona
Mouna Ayadi
Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul
Consuelo Buttigliero
Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng
Kim N. Chi
Caroline S. Clarke
Noel Clarke
Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke
Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun
Felix Y. Feng
Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis
Susan Halabi
Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope
Lisa G. Horvath
Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones
Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal
Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78,
Mika P. Matikainen 79,
Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship ,
Michael J. Morris 85,
Hind Mrabti 86,
Deborah Mukherji
@declangmurphy
Vedang Murthy
Shingai B.A. Mutambirwa
@DrPaulNguyen
William K. Oh
@piet_ost
Joe M. O’Sullivan
Anwar R. Padhani
Chris Parker
Darren M.C. Poon
Colin C. Pritchard
Danny M Rabah
Dana Rathkopf
Robert E. Reiter
Raphaele Renard-Penna
Charles J. Ryan
Fred Saad
Juan Pablo Sade
Shahneen Sandhu
Oliver A. Sartor
Edward Schaeffer
Howard I. Scher
Nima Sharifi
Iwona A. Skoneczna
Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki
Mary-Ellen Taplin
Camilla Thellenberg-Karlsson
Derya Tilki
Levent N. Türkeri
Hiroji Uemura
@DrYukselUrun
Claire L. Vale
Neha Vapiwala
Jochen Walz
Kosj Yamoah
Dingwei Ye
Evan Y. Yu
Almudena Zapatero
@AOmlin
Emeline COLOMBA retweeted
🔔👊 ESMO Presidential session : Pr Domenica Lorusso has presented the final OS results of the international phase III ENGOT study ENGOT-cx11/Keynote A18 (Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer)
#ESMO24 #cervicalcancer #ENGOT
Emeline COLOMBA retweeted
👏🏾52 vs 28% ORR is impressive !!
🤞🏿Awaiting PFS/OS data
👀We need to better understand characteristics of optimal 💩 donors in this setting
🙏🏽I praise the med community to say « fecal transfer » or « graft » more appropriate than fecal transplantation (stool≠organ)
#ESMO24
Fecal microbiota transplantation doubles objective response with systemic therapy in mRCC #kidneycancer (axitinib+ pembrolizumab). 👇 Congrats @ciccarese_c for the wonderful talk (validates data from @NazliDizman @montypal ) @myESMO #ESMO24 @OncoAlert @kidneycan @urotoday
